Biotest AG: Biotest significantly increases sales, EBIT above the high level of last year
Biotest AG / Preliminary Results
16.02.2010 08:52
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biotest significantly increases sales, EBIT above the high level of last
year
Dreieich, 16 February 2010. According to preliminary and unaudited figures,
the Biotest Group (Continued Business) recorded sales of EUR 440.2 million
in financial year 2009, an increase of 14.1% compared to the previous year
(EUR 385.9 million). Earnings before interest and tax (EBIT) are in the
range of EUR 61 million versus EUR 59 million in 2008.
Including the contribution of the Segment Medical Diagnostics - to be
discontinued in 2010 (discontinued operations) - sales increased by 13.7%
to EUR 481.0 million.
In the Plasma Protein segment, Biotest increased sales by 14.9% to EUR
390.1 million compared to the previous year (EUR 339.5 million).
In the Microbiological Monitoring segment, sales were up by 8% to EUR 50.1
million versus EUR 46.4 million in 2008. The reporting for this segment
includes parts of the former segment Medical Diagnostic which have not been
divested. The previous year's figures have been adjusted accordingly.
Biotest will publish final results for the Financial Year 2009 on March
19th, 2010, the annual report will be published on the same day.
The Annual General Meeting of Biotest AG will take place on May 6th, 2010
in Frankfurt a.M.
Biotest Aktiengesellschaft
The Executive Management Board
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide sales,
Biotest has specialised primarily in the areas of application of immunology
and haematology. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In the Biotherapeutic segment, Biotest researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. The products of the
Microbiological Monitoring segment are primarily used in hygiene
monitoring. Biotest has more than 1,900 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
16.02.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
